Stay updated on REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Sign up to get notified when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.
Screenshot error
Open in browserReport Problem
Clouds background image

Latest updates to the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:57:00.000Z thumbnail image
  4. Check
    23 days ago
    No Change Detected
  5. Check
    30 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study objectives and criteria for a clinical trial on natalizumab for relapsing-remitting multiple sclerosis, while retaining some key identifiers and a version update.
    Difference
    19%
    Check dated 2025-04-16T02:08:22.000Z thumbnail image
  6. Check
    38 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-08T23:11:38.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T18:27:37.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    2%
    Check dated 2025-03-03T22:25:10.000Z thumbnail image
  9. Check
    95 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    2%
    Check dated 2025-02-10T10:06:28.000Z thumbnail image

Stay in the know with updates to REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REFINE: Natalizumab Regimens in Relapsing MS Clinical Trial page.